Supreme Court flags 'daylight dacoity' in cancer drug pricing
The Supreme Court on Tuesday expressed shock over the overpricing of essential cancer medicines, noting one drug carried a printed MRP of ₹27,000 though it was supplied to retailers for ₹2,700. A Bench of Justices Vikram Nath and Sandeep Mehta called it "broad daylight dacoity" with patients and said authorities meant to act were silent. The remarks came while hearing two petitions on drug price control and prescription of generic medicines. Additional Solicitor General K.M. Nataraj said the Centre was not treating it as adversarial litigation. Next hearing: September 29, 2026.
Source
The Hindu — National · read the original report ↗
Desk check · compared with the source
What the desk checked (5)
- An essential cancer drug carried an MRP of ₹27,000 while its price to retailer was ₹2,700. — Figure appears in source, attributed to observations of the Supreme Court Bench; no independent verification possible.
- The Bench of Justices Vikram Nath and Sandeep Mehta called the overpricing 'broad daylight dacoity' with patients. — Direct quote attributed to the named Bench in the source.
- Additional Solicitor General K.M. Nataraj said the government was not treating the matter as adversarial litigation. — Attributed to named counsel for the Centre in the source.
- One petition sought strict price control under the Drugs (Prices Control) Order, 2013; another sought disciplinary action against doctors not prescribing generic medicines. — Described in source as contents of the petitions; pleas not independently examined.
- The matter was posted for further hearing on September 29, 2026. — Date stated in source; hearing is prospective and subject to change.
Analysts’ view opinion
The language from the Bench — "broad daylight dacoity" — is not legalese; it is political vocabulary. Drug price control has so far been a technical, administrative file, but a single legible number (₹2,700 to the retailer, ₹27,000 on the label) is exactly the kind of fact that travels to ordinary voters. The Centre's statement that it does not see this as adversarial litigation is a strategic choice: instead of defending, it can position itself alongside the court and shift the spotlight onto the regulatory chain and the companies.
- The observation that "authorities supposed to act are silent" is effectively a question about regulatory performance, which raises political pressure on the executive machinery.
- The court's reference to people selling houses and ornaments for treatment is emotionally resonant material that opposition voices can pick up easily.
- By declining an adversarial posture through the Additional Solicitor General, the Centre keeps the option of converting judicial initiative into its own reform credit.
- Pharma manufacturers and retail trade bodies are organised interest groups, so any tightening of price control is likely to meet resistance from them.
- With the next hearing set for September 29, 2026, the issue returns to public debate within days rather than fading.
What to watch — Watch what affidavit or action plan the Centre files at the September 29 hearing, and whether any policy signalling follows on generic prescribing.
The story records only oral observations from the Bench — it does not establish which drug or company is involved, which regulator allegedly failed, or that any order or policy change has been issued.
Deep dive
Research brief · 8 facts · 3 dates · exam-readyThe brief
Context
The Supreme Court is hearing two petitions on medicine pricing and prescribing practices in India. One seeks strict enforcement of price control over essential drugs under the Drugs (Prices Control) Order, 2013, alleging unethical overpricing by pharma companies and retailers; the other seeks disciplinary action against doctors who do not prescribe generic medicines. During the hearing on September 22, 2026, a Bench of Justices Vikram Nath and Sandeep Mehta was told of an essential cancer drug with a printed MRP of ₹27,000 though its price to retailer (PTR) was ₹2,700, and described the gap as "broad daylight dacoity" with patients.
Key facts
- An essential cancer drug carried a printed MRP of ₹27,000 while its price to retailer (PTR) was ₹2,700 — an MRP 10 times the rate supplied to retailers.
- The Bench of Justices Vikram Nath and Sandeep Mehta called the pricing "broad daylight dacoity with patients" and "absolute rampage and carnage".
- The court said it was "very surprising that the authorities who are supposed to take action on this are silent".
- The court observed that price fixation was a major issue and asked how patients could be cheated like this.
- The Bench noted: "People sell their houses, ornaments to get treatment."
- Additional Solicitor General K.M. Nataraj, for the Centre, said the government was not treating the matter as adversarial litigation.
- One petition sought strict price control under the Drugs (Prices Control) Order, 2013, to curb violations of the price-fixing mechanism in the drug supply chain.
- The other petition sought disciplinary action against registered medical practitioners for not prescribing generic medicines; the case was posted for September 29, 2026.
Timeline
- September 22, 2026Supreme Court Bench of Justices Vikram Nath and Sandeep Mehta hears two drug-related petitions; terms cancer drug overpricing "broad daylight dacoity".
- September 23, 2026Report of the hearing published.
- September 29, 2026Matter posted for further hearing.
Who has a stake
- Cancer patients and their families — Bear the cost of drugs priced up to 10 times the price to retailer; the court noted people sell houses and ornaments for treatment.
- Supreme Court Bench (Justices Vikram Nath, Sandeep Mehta) — Examining price fixation and enforcement failures; considering directions on price control and generic prescribing.
- Union Government (represented by ASG K.M. Nataraj) — Said it is not treating the litigation as adversarial; responsible for price control enforcement.
- Pharmaceutical companies and retailers — Accused in the petitions of unethical overpricing and disproportionate profit-making through unfair trade practices.
- Registered medical practitioners — One plea seeks disciplinary action against them for not prescribing generic medicines.
- Regulatory authorities meant to enforce price control — Criticised by the court for remaining silent despite the MRP-PTR gap.
Why it matters
Cancer treatment is among the largest drivers of catastrophic health spending in India, and a tenfold gap between a drug's MRP and its price to retailer directly translates into out-of-pocket costs for patients. The Court's remarks put the spotlight not just on pharma pricing but on the silence of the authorities charged with enforcing the Drugs (Prices Control) Order, 2013. The linked question of generic prescribing goes to whether cheaper equivalents actually reach patients.
UPSC angle
Prelims pointers
- Drugs (Prices Control) Order, 2013 — the order under which the petition seeks strict price control over essential medicines.
- MRP vs PTR: in the cited case, MRP ₹27,000 against price to retailer ₹2,700 — a 10-fold gap.
- Bench hearing the matter: Justices Vikram Nath and Sandeep Mehta.
- Additional Solicitor General K.M. Nataraj appeared for the Centre in one of the pleas.
- Hearing date: September 22, 2026; next hearing posted for September 29, 2026.
- Second plea seeks disciplinary action against registered medical practitioners for not prescribing generic medicines.
Mains framing
The Supreme Court's observation that an essential cancer drug priced at ₹2,700 to retailers carried a printed MRP of ₹27,000 exposes a structural failure in India's drug price regulation rather than an isolated case of profiteering. The petitions before the Court locate the problem in two places: weak enforcement of the price-fixing mechanism under the Drugs (Prices Control) Order, 2013, which allows disproportionate margins along the supply chain, and prescribing practices that steer patients towards branded formulations instead of cheaper generics. The consequence is catastrophic out-of-pocket expenditure — the Bench itself noted that people sell houses and ornaments to fund treatment — and a loss of trust in both regulators and practitioners; the Court specifically flagged the silence of authorities "supposed to take action". A way forward implied by the record before the Court would involve tighter scrutiny of the MRP-PTR spread for essential medicines, active enforcement against violations of the price-fixing mechanism, and accountability for non-prescription of generics. The Centre's statement that it is not treating the case as adversarial suggests scope for a cooperative remedy, which the next hearing on September 29, 2026 will test.
Key terms
- MRP (Maximum Retail Price)
- The printed ceiling price at which a medicine may be sold to the consumer; ₹27,000 in the cancer drug cited.
- PTR (Price to Retailer)
- The price at which a drug is supplied to the retailer; ₹2,700 in the cited case, a tenth of the MRP.
- Drugs (Prices Control) Order, 2013
- The order governing price control of medicines in India, under which the petition seeks strict enforcement.
- Generic medicines
- Non-branded equivalents of drugs; one plea seeks disciplinary action against doctors who fail to prescribe them.
- Additional Solicitor General (ASG)
- Senior law officer representing the Union Government in court; K.M. Nataraj appeared for the Centre here.
- Adversarial litigation
- Litigation contested between opposing sides; the Centre said it was not treating this case as such.
Practice questions
- The Supreme Court described a tenfold gap between the MRP and price to retailer of an essential cancer drug as "broad daylight dacoity". Examine the regulatory gaps in India's drug price control framework that such a gap reveals.
- Discuss whether mandating the prescription of generic medicines by registered medical practitioners can meaningfully reduce out-of-pocket health expenditure in India.
- "Price fixation is a major issue." In the light of the Supreme Court's observations, critically assess the enforcement of the Drugs (Prices Control) Order, 2013.
Grounded only in the source report — figures and dates are the source's, not inferred.